Health Care & Hospital Law,
Government
Aug. 20, 2024
Legal and political battles threaten Medicare drug price negotiation program
The Inflation Reduction Act (IRA) of 2022 established a voluntary Drug Price Negotiation Program to reduce the cost of certain drugs for Medicare beneficiaries and taxpayers. Drug manufacturers and their allies have brought a wave of lawsuits challenging the law.
John H. Minan
Emeritus Professor of Law, University of San Diego School of Law
Professor Minan is a former attorney with the Department of Justice in Washington, D.C. and the former chairman of the San Diego Regional Water Quality Board.
In August 2022, President Joseph Biden signed the Inflation Reduction Act (IRA), which among other things created the voluntary Drug Price Negotiation Program. It is designed to rein in the high cost of certain single source, high-priced drugs for Medicare beneficiaries and the taxpayers by using the federal government's purchasing power with drug manufacturers.
The program is expected to save billions of dollars for the government and beneficiaries. Pr...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In